exRNAdisease

Entry Detail

---



General Information

Database ID: exR0082340 RNA Name: STK4 RNA Type: mRNA Chromosome: chr20 Starnd: + Coordinate: Start Site(bp): 44966479 End Site(bp): 45080021 External Links: ENSG00000101109

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABCF2 chr7 151207837 151227166 - AC245033.1 chr15 82536788 82573194 - AGPAT1 chr6 32168212 32178096 - AGTRAP chr1 11736084 11754802 + AKR1B1 chr7 134442356 134459284 - AKT3 chr1 243488233 243851079 - ALDH9A1 chr1 165662216 165698863 - miRNA targets: miRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa-let-7a-5p chr9 94175962 94175983 + hsa-miR-24-3p chr9 95086064 95086085 + hsa-miR-122-5p chr18 58451088 58451109 + hsa-miR-130a-3p chr11 57641252 57641273 + hsa-miR-135a-5p chr12 97563834 97563856 + hsa-miR-138-5p chr16 56858527 56858549 + hsa-miR-130b-3p chr22 21653354 21653375 + hsa-miR-362-5p chrX 50008968 50008991 + hsa-miR-135b-5p chr1 205448361 205448383 - hsa-miR-1224-5p chr3 184241405 184241423 + hsa-miR-1276 chr15 85770548 85770567 - hsa-let-7c-5p chr21 16539838 16539859 + circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC087190.3 chr16 9104848 9113181 + AC245033.4 chr15 82533175 82540008 - Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA